Study backs anti-TNFs for rheumatology patients with COVID-19
Monotherapy gave the best outcomes in an analysis of data from three registries
Pooled data from three international COVID-19 registries support the use of TNF inhibitor monotherapy in patients with rheumatoid arthritis and other immune-mediated inflammatory diseases.
But, compared to TNF inhibitor monotherapy, some other therapies — including methotrexate monotherapy, Janus kinase (JAK) inhibitors or azathioprine/6-mercaptopurine — worsen the odds of severe COVID-19 in such patients, the investigators report.
